Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)--Telesis Bio® Inc., a provider of intelligent, on-premises DNA synthesis for AI labs, today announced a strategic focus on serving AI discovery teams with DNA synthesis infrastructure that connects computational design to experimental data. The company’s new website, launched November 3, reflects this direction. Telesis Bio will share its strategy at PEGS Europe 2026, taking place November 16–19 in Lisbon, Portugal. AI is accelerating the design of therapeutic candida